Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Minai-Azary Jennifer Lynn	2. Date of Event Requiring Statement (MM/DD/YYYY) 2/1/2021	3. Issuer Name and Ticker or Trading Symbol Millendo Therapeutics, Inc. [MLND]
(Last)        (First)        (Middle) C/O MILLENDO THERAPEUTICS, INC., 110 MILLER AVENUE, SUITE 100	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                          _____ 10% Owner ___X___ Officer (give title below)        _____ Other (specify below) Chief Financial Officer /
(Street) ANN ARBOR, MI 48104       (City)              (State)              (Zip)	5. If Amendment, Date Original Filed(MM/DD/YYYY)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	8/21/2023	Common Stock	2969.0	$1.08	D
Stock Option (right to buy)	(1)	5/27/2024	Common Stock	989.0	$2.69	D
Stock Option (right to buy)	(1)	1/27/2026	Common Stock	12382.0	$4.44	D
Stock Option (right to buy)	(1)	11/2/2026	Common Stock	12840.0	$8.47	D
Stock Option (right to buy)	(2)	8/23/2028	Common Stock	11160.0	$16.4	D
Stock Option (right to buy)	(3)	1/31/2029	Common Stock	18000.0	$10.48	D
Stock Option (right to buy)	(4)	6/20/2029	Common Stock	7000.0	$11.59	D
Stock Option (right to buy)	(5)	1/30/2030	Common Stock	20000.0	$7.94	D
Stock Option (right to buy)	(6)	5/24/2030	Common Stock	20000.0	$2.0	D

Explanation of Responses:
(1)	Shares subject to this option are fully vested.
(2)	Twenty-five percent (25%) of the shares subject to this option vested on August 20, 2019, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
(3)	Twenty-five percent (25%) of the shares subject to this option vested on January 31, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
(4)	Twenty-five percent (25%) of the shares subject to this option vested on June 20, 2020, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
(5)	Twenty-five percent (25%) of the shares subject to this option vested on January 31, 2021, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
(6)	Fifty percent (50%) of the shares subject to this option vested on December 31, 2020, and one twelfth (1/12th) of the remaining shares subject to this option shall vest in equal monthly installments thereafter, subject to the Reporting Person continuing to provide service to the Issuer through each such date.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Minai-Azary Jennifer Lynn C/O MILLENDO THERAPEUTICS, INC. 110 MILLER AVENUE, SUITE 100 ANN ARBOR, MI 48104			Chief Financial Officer

Signatures
/s/ Jennifer L. Minai-Azary		2/9/2021
**Signature of Reporting Person		Date